Preclinical efficacy of gemcitabine in MLL-rearranged infant acute lymphoblastic leukemia
The treatment of children diagnosed with acute lymphoblastic leukemia (ALL) has improved significantly over recent decades, with 5-year event-free survival (EFS) approaching 85% [1]. However, 5-year EFS for infants diagnosed at less than 1 year of age with MLL-rearranged ALL remains less than 40...
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal Article |
| Language: | English |
| Published: |
2020
|
| Online Access: | http://hdl.handle.net/20.500.11937/79575 |
| _version_ | 1848764077927563264 |
|---|---|
| author | Wander, P. Cheung, Laurence Pinhanҫos, S.S. Jones, L. Kerstjens, M. Arentsen-Peters, S.T.C.J.M. Singh, S. Chua, G.A. Castro, P.G. Schneider, P. Dolman, M.E.M. Koopmans, B. Molenaar, J.J. Pieters, R. Zwaan, C.M. Kotecha, Rishi Stam, R.W. |
| author_facet | Wander, P. Cheung, Laurence Pinhanҫos, S.S. Jones, L. Kerstjens, M. Arentsen-Peters, S.T.C.J.M. Singh, S. Chua, G.A. Castro, P.G. Schneider, P. Dolman, M.E.M. Koopmans, B. Molenaar, J.J. Pieters, R. Zwaan, C.M. Kotecha, Rishi Stam, R.W. |
| author_sort | Wander, P. |
| building | Curtin Institutional Repository |
| collection | Online Access |
| description | The treatment of children diagnosed with acute lymphoblastic leukemia (ALL) has improved significantly over
recent decades, with 5-year event-free survival (EFS)
approaching 85% [1]. However, 5-year EFS for infants
diagnosed at less than 1 year of age with MLL-rearranged
ALL remains less than 40% [2]. MLL-rearranged infant
ALL is both clinically and biologically distinct from other
childhood ALL subtypes, which is reflected by a unique
gene expression profile [3], a remarkably silent mutational
landscape [4], and pronounced resistance to currently
applied chemotherapeutics [5]. |
| first_indexed | 2025-11-14T11:13:38Z |
| format | Journal Article |
| id | curtin-20.500.11937-79575 |
| institution | Curtin University Malaysia |
| institution_category | Local University |
| language | eng |
| last_indexed | 2025-11-14T11:13:38Z |
| publishDate | 2020 |
| recordtype | eprints |
| repository_type | Digital Repository |
| spelling | curtin-20.500.11937-795752020-09-03T06:11:15Z Preclinical efficacy of gemcitabine in MLL-rearranged infant acute lymphoblastic leukemia Wander, P. Cheung, Laurence Pinhanҫos, S.S. Jones, L. Kerstjens, M. Arentsen-Peters, S.T.C.J.M. Singh, S. Chua, G.A. Castro, P.G. Schneider, P. Dolman, M.E.M. Koopmans, B. Molenaar, J.J. Pieters, R. Zwaan, C.M. Kotecha, Rishi Stam, R.W. The treatment of children diagnosed with acute lymphoblastic leukemia (ALL) has improved significantly over recent decades, with 5-year event-free survival (EFS) approaching 85% [1]. However, 5-year EFS for infants diagnosed at less than 1 year of age with MLL-rearranged ALL remains less than 40% [2]. MLL-rearranged infant ALL is both clinically and biologically distinct from other childhood ALL subtypes, which is reflected by a unique gene expression profile [3], a remarkably silent mutational landscape [4], and pronounced resistance to currently applied chemotherapeutics [5]. 2020 Journal Article http://hdl.handle.net/20.500.11937/79575 10.1038/s41375-020-0895-9 eng restricted |
| spellingShingle | Wander, P. Cheung, Laurence Pinhanҫos, S.S. Jones, L. Kerstjens, M. Arentsen-Peters, S.T.C.J.M. Singh, S. Chua, G.A. Castro, P.G. Schneider, P. Dolman, M.E.M. Koopmans, B. Molenaar, J.J. Pieters, R. Zwaan, C.M. Kotecha, Rishi Stam, R.W. Preclinical efficacy of gemcitabine in MLL-rearranged infant acute lymphoblastic leukemia |
| title | Preclinical efficacy of gemcitabine in MLL-rearranged infant acute lymphoblastic leukemia |
| title_full | Preclinical efficacy of gemcitabine in MLL-rearranged infant acute lymphoblastic leukemia |
| title_fullStr | Preclinical efficacy of gemcitabine in MLL-rearranged infant acute lymphoblastic leukemia |
| title_full_unstemmed | Preclinical efficacy of gemcitabine in MLL-rearranged infant acute lymphoblastic leukemia |
| title_short | Preclinical efficacy of gemcitabine in MLL-rearranged infant acute lymphoblastic leukemia |
| title_sort | preclinical efficacy of gemcitabine in mll-rearranged infant acute lymphoblastic leukemia |
| url | http://hdl.handle.net/20.500.11937/79575 |